Breast Cancer


Share

Program Content

Activities

  • NATALEE N0 Subgroup
    NATALEE: Subgroup Analysis of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With Stage II/III Node-Negative HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2024

    Expires: June 01, 2025

  • postMONARCH
    postMONARCH: Abemaciclib + Fulvestrant vs Fulvestrant Monotherapy for HR+/HER2- Advanced BC After Progression on CDK4/6 Inhibitor + ET
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2024

    Expires: June 02, 2025

  • SACI-IO HR+
    SACI-IO HR+: Phase II Trial of Sacituzumab Govitecan ± Pembrolizumab in HR+/HER2- Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • DESTINY-Breast07
    DESTINY-Breast07: Trastuzumab Deruxtecan ± Pertuzumab for Previously Untreated HER2+ Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • DESTINY-Breast06
    DESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs Chemotherapy in Previously Treated HR+/HER2-Low or Ultralow MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2024

    Expires: June 04, 2025

  • I-SPY 2.2 Dato-DXd + Durva
    I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • A BRAVE
    A-BRAVE: Phase III Trial of Adjuvant Avelumab vs Observation in Patients With Early TNBC With Residual Disease Post Neoadjuvant CT or at High Risk After Surgery and Adjuvant CT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • ASCO to Clinic: Breast Cancer
    Conference to Clinic: Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 21, 2024

    Expires: June 20, 2025

  • ASCO 2024 Breast Cancer WC
    Conference to Clinic: Breast Cancer
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 02, 2024

    Expires: July 01, 2025

  • ASCO 2024 Breast Cancer
    Key Studies in Breast Cancer: Independent Conference Coverage of the 2024 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 14, 2024

    Expires: February 13, 2025

Faculty

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation